Network pharmacological study and experimental verification of punicalagin in treatment of depression
- Author:
Ping XU
1
;
Shu-Yun HUANG
1
;
Hong-Ming GUO
1
;
Yan-Ping LIU
1
;
Zong-Yuan HONG
1
;
Shu-Zhi ZHONG
1
Author Information
- Publication Type:Journal Article
- Keywords: CUMS; depression; liquid chromatography-mass spectrometry(LC-MS/MS); molecular docking; network pharmacology; Punicalagin
- From: Chinese Pharmacological Bulletin 2022;38(5):755-760
- CountryChina
- Language:Chinese
- Abstract: Aim To study and verify the effeet and po¬tential mechanism of punicalagin ( Pun) in the treat-ment of depression by preliminary experiments based on network pharmacology.Methods The intersection genes of Pun and depression were obtained through the database, and protein interaction ( PPI ), GO and KEGG were enriched and analyzed.Molecular docking technology was used to preliminarily verify the binding ability of Pun active components to core therapeutic targets.The depression model of CUMS mice was es¬tablished by chronic stress, and Pun was administered by gavage.Open field experiments were conducted to investigate behavior changes.The content of neuro¬transmitters in hippocampus was detected by liquid chromatography-mass spectrometry ( LC-MS / MS ).Results The results of network pharmacology showed that Pun had 76 targets involved in the occurrence of depression, and PPI network showed that the intersec¬tion genes were closely related.Proteoglycans, lipids and atherosclerosis enriched in cancer.The results of molecular docking showed that there was a good bind¬ing between the compound and the target protein.The results of animal experiments showed that Pun could in¬crease the exploration desire of open field experimental mice.The levels of DA and 5-HT in hippocampus in-creased ( P < 0.05, P < 0.01 ).Conclusions Pun can significantly reduce the depressive state of mice, and its mechanism may act on ALB and AKT1 targets, mediate proteoglycans, lipids and atherosclerotic path¬ways in cancer, so as to improve the secretion of neu¬rotransmitters.
